

*The Journal of Urology*® contains 3 sections: Adult Urology, Pediatric Urology and Urological Survey. **Original clinical and translational research studies will be considered for publication in the Adult and Pediatric Urology Sections. Translational research manuscripts must have a clear and proximate translation to patient care, and only preclinical scientific studies that have the direct potential to translate into new and improved standards of care will be reviewed.**

All communications concerning editorial matters should be sent to:

*The Journal of Urology*®

Publications Department

American Urological Association

1000 Corporate Boulevard

Linthicum, MD 21090

Telephone (410) 689-3922, FAX (410) 689-3906

e-mail: publications@auanet.org

## MANUSCRIPT SUBMISSION

Authors must submit their manuscripts through the Web-based tracking system at <https://www.editorialmanager.com/ju>. The site contains instructions and advice on how to use the system, guidance on the creation/scanning and saving of electronic art, and supporting documentation. In addition to allowing authors to submit manuscripts on the Web, the site allows authors to follow the progression of their manuscript through the peer review process. Authors are asked **NOT** to mail hard copies of the manuscript to the editorial office. They may, however, mail to the editorial office any material that cannot be submitted electronically.

**For potentially acceptable manuscripts, the period between receipt of all reviews and when an editorial decision is made is usually longer.**

**Rapid Review Manuscripts** that contain important and timely information will be reviewed by 2 consultants and the editors within 72 hours of receipt, and authors will be notified of the disposition immediately thereafter. **The authors must indicate in their submittal letter why they believe their manuscript warrants rapid review.** A \$250 processing fee should be forwarded with the manuscript at the time of submission. Checks should be made payable to the American Urological Association. If the editors decide that the paper does not warrant rapid review, the fee will be returned to the authors, and they may elect to have the manuscript continue through the standard review process. Payment for rapid review guarantees only an expedited review and not acceptance.

**Original Clinical and Translational Research Articles:** Authors must adhere to the CONSORT guidelines for clinical and randomized trials (<http://www.consort-statement.org/downloads>). Manuscripts should be arranged as follows: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions, References, Tables, Legends. The title page should contain a concise, descriptive title, the names, email addresses and affiliations of all authors, and a brief descriptive runninghead not to exceed 50 characters. One to five key words should be typed at the bottom of the title page. These words should be identical to the medical subject headings (MeSH) that appear in the Index Medicus of the National Library of Medicine. The abstract should not exceed 250 words (abbreviations are not to be substituted for whole words) and must conform to the following style: Purpose, Materials and Methods, Results and Conclusions.

**References** should not exceed 30 readily available citations for all articles (except Review Articles). Self-citations should be kept to a minimum. References should be cited by superscript numbers as they appear in the text, and they should not be alphabetized. References should include the names and initials of the first 3 authors, the complete title, the abbreviated journal name according to the Index Medicus of the National Library of Medicine, the volume, the beginning page number and the year. References to book chapters should include names and initials of the first 3 chapter authors, chapter title, book title and edition, names and initials of the first 3 book editors, city of publisher, publisher, volume number, chapter number, page range and year. In addition to the above, references to electronic publications should include type of medium, availability statement and date of accession. The statistical methods should be indicated and referenced. Enough information should be presented to allow an independent critical assessment of the data.

**Digital illustrations and tables** should be kept to a necessary minimum and their information should not be duplicated in the text. No more than 10 illustrations should accompany the manuscript for clinical articles. Magnifications for photomicrographs should be supplied and graphs should be labeled clearly. Reference to illustrations, numbered with Arabic numerals, must be provided in the text. Blurry or unrecognizable illustrations are not acceptable. Visit <http://links.lww.com/ES/A42> for detailed instructions for digital art. The use of color is encouraged at no charge to the authors.

Tables should be numbered and referred to in the text. In general, they should present summarized rather than individual raw data. Due to page constraints caused by the large number of high quality manuscripts being submitted to *The Journal of Urology*, the editors find it necessary to offer publishing alternatives. Therefore, authors may be requested to post tables and illustrations as supplementary material on The Journal website at no charge or print tables and illustrations in the article at a per page rate of \$270.

**Review Articles** are to be prepared in the same format as that of an Original Clinical Article. For comprehensive or critical reviews, authors must adhere to the AMSTAR criteria ([https://amstar.ca/Amstar\\_Checklist.php](https://amstar.ca/Amstar_Checklist.php)). For systematic reviews authors must adhere to the PRISMA guidelines (<http://www.prisma-statement.org/documents/PRISMA%202009%20checklist.pdf>).

**Special Articles** are scientific reports of original clinical research and state-of-the-art topics, and are designated as such by the Editors. The format is the same as that of an Original Clinical Article.

**New Technology and Techniques** feature high quality manuscripts that describe the innovative clinical application of new technology or techniques in all disciplines of urology, and are designated as such by the Editors. Addressing diagnosis or management of urological conditions, this feature covers the categories of 1) cutting-edge technology, 2) novel/modified techniques and 3) outcomes data derived from use of 1 and/or 2. The format is the same as that of an Original Clinical Article, although fewer words are preferred to allow more space for illustrations.

**JU Forum.** The JU Forum is a feature for presentations of pertinent new ideas, perspective on advances in the field, recommendations for novel strategies, topics related to training and education, and discussion of relevant socioeconomic considerations that impact patient care. These concise commentaries should be no more than 1,500 words without graphics or 1,200 words with a single table or illustration and 10 references. The preferred number of authors is three or fewer from no more than two separate institutions, although exceptions can be made in special circumstances.

**Letters to the Editor** should be useful to urological practitioners. The length should not exceed 500 words. Only Letters concerning articles published in the Journal within the last year are considered.

**Video Clips** may be submitted for posting on The Journal web site. They are subject to peer review. Video files must be compressed to the smallest possible size that still allows for high resolution and quality presentation. The size of each clip should not exceed 100MB. File size limitation is intended to ensure that end-users are able to download and view files in a reasonable time frame. If files exceed the specified size limitation, they will not be posted to the web site and returned to the author for resubmission.

## JOURNAL ETHICS

*The Journal of Urology* expects the highest ethical standards from their authors, reviewers and editors when conducting research, submitting papers and throughout the peer review process. *The Journal of Urology* is listed among those journals that follow the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE) (<http://www.icmje.org/recommendations/>).

**Plagiarism** – Plagiarism is scientific misconduct and will be addressed as such. When plagiarism is detected at any time before publication, the editorial office will take appropriate action as directed by the standards set forth by the Committee on Publication Ethics (COPE). For additional information, please visit <http://www.publicationethics.org>.

**Redundant or Duplicate Publication** – Duplicate or redundant publication is a publication that overlaps substantially with one already published, in press or in an electronic media submission. (ICMJE. <http://www.icmje.org/recommendations/browse/publishingand-editorialissues/overlapping-publications.html>)

Duplicate or redundant submission is the same manuscript (or the same data) that is submitted to different journals at the same time. International copyright laws, ethical conduct and cost-effective use of resources require that readers can be assured that what they are reading is original. (ICMJE. <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlappingpublications.html>)

Submitted manuscripts should not have been published or currently submitted elsewhere. Duplicate publication will be grounds for prompt rejection of the submitted manuscript. If the editor was not aware of the violation and the article has been published, a notice of duplicate submission and the ethical violation will be published.

**Conflicts of Interest** – At the point of submission, policy requires that each author reveals any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications or opinions stated, including pertinent

commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships or direct academic competition.

If the manuscript is accepted, Conflict of Interest information will be communicated in a published statement. Disclosure form for authors to complete is attached at the end of the Instructions for Authors.

**Data Sharing Policy** – *The Journal of Urology* encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors may provide a data availability statement, including a link to the repository they have used, in order that this statement can be published in their paper. Shared data should be cited.

**Permissions to Reproduce Previously Published Material** – For permissions to reproduce, please see the license under which the individual article has been published. Articles published in *The Journal of Urology* are copyrighted by the society owner: American Urological Association Education and Research, Inc.

**Patient Consent Forms** – The protection of a patient's right to privacy is essential. Please collect and keep copies of patients' consent forms on which patients or other subjects of your experiments clearly grant permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material.

A statement to the effect that such consent had been obtained must be included in the Materials and Methods section of your paper. If necessary the editors may request a copy of any consent forms.

**Ethics Committee Approval** – All articles dealing with original human or animal data must include a statement on ethics approval. For studies conducted on human participants you must state clearly that you obtained written informed consent from the study participants; please also look at the latest version of the Declaration of Helsinki. Institutional review board, including the IRB number, ethics committee or ethical review board study approval must be stated in the manuscript. If ethics clearance was not necessary, or if there was any deviation from these standard ethical requests, please state why it was not required. Please note that the editors may ask you to provide evidence of ethical approval. If you have approval from a National Drug Agency (or similar) please state this and provide details, as this can be particularly useful when discussing the use of unlicensed drugs.

**Author responsibilities** – Manuscripts must be accompanied by a cover letter. The letter should include the complete address, telephone number, FAX number and e-mail address of the designated corresponding author as well as the names of potential reviewers. The corresponding author is responsible for providing the email addresses for all authors, indicating the source of extra institutional funding, in particular that provided by commercial sources, accuracy of the references and all statements made in their work, including changes made by the copy editor. The corresponding author also certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.

All clinical trials must be registered in a public trials registry at or before the time of first patient enrollment and the registration number provided as a condition of consideration for publication.

It is the responsibility of every person listed as an author of an article published in *The Journal of Urology* to follow the practice and ethical guidelines set forth by the International Committee of Medical Journal Editors (<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two>).

According to the ICJME authorship is based on the following 4 criteria:

- Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors must meet ALL 4 criteria for authorship. Those who do meet ALL 4 criteria will be identified as authors and their names will be printed in the byline of the article.

When a large, multicenter group or committee has conducted the work, the group should identify as authors only those individuals who fulfill ALL of the above requirements and accept direct responsibility for the manuscript. The corresponding author must clearly indicate the preferred citation and identify all individual authors as well as the group name. Contributors to the study who do not meet ALL 4 criteria of authorship will be acknowledged in an Appendix and identified as Collaborators so their names can be indexed in MEDLINE. Examples of contributions that do not justify authorship are acquisition of funding, general supervision of a research group, served as scientific advisors, critically reviewed the study proposal, collected data, provided and cared for study patients, and participated in writing or technical editing of the manuscript.

Authors are expected to submit complete and correct manuscripts. Published manuscripts become the sole property of *The Journal of Urology* and copyright will be taken out in the name of the American Urological Association Education and Research, Inc.

**The electronic AUA Disclosure and Author Submission Requirement forms at the end of this document will be sent to each individual author of acceptable manuscripts to be completed, signed and returned electronically to [publications@auanet.org](mailto:publications@auanet.org). Articles will not be published until all completed forms are received.**

**Upon author request, all accepted NIH funded articles will be deposited by the publisher to PubMed Central for public access 12 months after the publication date.**

#### OPEN ACCESS

The American Urological Association journals offer a hybrid Open Access (OA) option to authors whose articles have been accepted for publication. Authors submitting work to *The Journal of Urology* will be given the opportunity to select the OA option at the revision stage of the peer review process, contingent upon acceptance of the paper. This choice has no influence on the peer review and acceptance process. All articles are subject to the standard peer review process and will be accepted or rejected based on their own merit.

Authors of accepted articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. OA articles will be freely available to read, download and share from the time of publication.

The article processing charge for *The Journal of Urology* is \$3,600 per article to be published under the Creative Commons Attribution-NonCommercial-No Derivatives 4.0 International Public License (CC BY NC ND 4.0). This license allows readers to disseminate and reuse the article, as well as share and reuse the scientific material. It does not permit commercial exploitation or the creation of derivative works without specific permission. To view a copy of this license, visit: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

The publication fee is charged on acceptance of the article and should be paid within 30 days by credit card by the author, funding agency or institution.

Payment must be received in full for the article to be published OA. Any additional standard publication charges will also apply.

Please find FAQ for OA at <http://links.lww.com/LWW-ES/A48>.

#### PAGE PROOFS AND CORRECTIONS

The corresponding author will receive electronic page proofs to check the typeset article before publication. Portable document format (PDF) files of the typeset pages and support documents (eg, reprint order form) will be sent to the corresponding author by e-mail. Complete instructions will be provided with the e-mail for downloading and printing the files and for faxing the corrected page proofs to the editorial office.

It is the author's responsibility to ensure that there are no errors in the proofs. Changes that have been made to conform to journal style will stand if they do not alter the author's meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The editorial office reserves the right to disallow extensive alterations. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Proofs must be checked carefully and corrections faxed within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.

ANALYTICAL REPORTING CHECKLIST FOR AUTHORS*	PUT PAGE NUMBERS IN APPROPRIATE COLUMN BELOW		
	ANIMAL EXPERIMENT	COHORT STUDY	RANDOMIZED TRIAL
1. Primary objective or major hypothesis of study			
2. Justification of sample size			
3. Participation rate if patients declined study			
4. Inclusion/exclusion criteria			
5. Source and initial number of patients			
6. Randomization method			
7. Blinding techniques			
8. Accrual dates			
9. Identification of transformations or categorization of variables, if done			
10. Justification if outliers were omitted from analysis			
11. Reasons for and analysis of patients withdrawn or protocol deviations			
12. Reporting of time between randomization and start of treatment			
13. Number of subjects who completed treatment(s)			
14. Treatment of missing values			
15. Frequency of side effects			
16. Identification of statistical software			
17. Justification if 1-tailed statistical tests are used			
18. Verification of statistical test assumptions			
19. Identification of all statistical tests with description or references			
20. Median followup time for censored patients			
21. Lost to followup expressed as the proportion of censored patients not evaluated during a specified time			
22. Reporting of the number of patients at risk over time			
23. Confidence intervals for effect sizes			

\*Guidelines for reporting statistics for clinical research in urology can be found at <https://www.auajournals.org/doi/10.1097/JU.0000000000000001>.

## Recommendations

For statistical guidelines, please see “Guidelines for Reporting of Statistics for Clinical Research in Urology” (<https://www.auajournals.org/doi/10.1097/JU.0000000000000001>).

For guidelines on tables and figures, please see “Guidelines for Reporting of Figures and Tables for Clinical Research in Urology” (<https://www.auajournals.org/doi/full/10.1097/JU.0000000000001096>).

## Manuscript Checklist

- 1. Manuscript word count is provided.
- 2. Manuscript does not exceed 2,500 words for Original Clinical Article.
- 3. Manuscript does not exceed 3,000 words for Translational Research Article.
- 4. Manuscript does not exceed 500 words for Letter to the Editor.
- 5. JU Forum does not exceed 1,500 words without graphics or 1,200 words with a table or illustration; no more than 10 references; and preferably no more than 3 authors from 2 institutions.
- 6. No more than 10 illustrations submitted.
- 7. Standard abbreviations are defined in a key at the end of the manuscript, and are consistent throughout the text.

- 8. Generic names are used for all drugs. Trade names are avoided.
- 9. Normal laboratory values are provided in parentheses when first used.
- 10. Research or project support/funding is noted.
- 11. Internal review board approval of study is indicated.
- 12. Registration number of clinical trial provided.
- 13. References are accurate, complete and in numerical order as they appear in the text, only the first 3 authors are listed.
- 14. No more than 30 references are cited, including references from the last 3 years.
- 15. A corresponding author and complete address, telephone and FAX numbers and e-mail address are provided.
- 16. Written permission from publishers to reproduce or adapt previously published illustrations or tables is included.
- 17. Informed consent forms for identifiable patient descriptions, photographs and pedigrees are included.
- 18. Analytical reporting checklist completed.
- 19. Gender and minorities are identified in collection and analyses of data.
- 20. Abbreviations for human genes are written in italicized capital letters; protein products are written in capital letters and are not italicized.
- 21. Abbreviations for animal genes are written in italics with only the first letter capitalized; protein products are written with only the first letter capitalized and are not italicized.
- 22. Name of validated system used for reporting complications/outcomes provided.

## American Urological Association (AUA) Disclosure Form for Authors

The AUA requires that prior to participating in programs all individuals make full disclosure of relationships, business transactions, presentations or publications related to healthcare or AUA activities. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. If you have questions, please review the [AUA Principles, Policies and Procedures for Managing Conflicts of Interest](#) or the [Frequently Asked Questions](#) document.

Each disclosure begins by asking the following question:

1. To whom does this disclosure apply?
  - Self
  - Family
  - Business Partner

**IF YOU HAVE NO DIRECT OR INDIRECT COMMERCIAL INCENTIVE WITH PUBLISHING THIS ARTICLE, THEN SKIP TO #7, AND SIGN AND RETURN THIS FORM**

2. What is the name of company or organization?

3. Is this a financial relationship?

- Yes Financial relationships are those relationships in which individuals benefit by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial relationships consist of employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.
- No Relationships should be reported regardless of whether or not compensation was received.

4. What is the type of relationship?

*All relationships in commercial interests should be reported.* A commercial interest is any entity producing, marketing, re-selling or distributing healthcare goods or services consumed by, or used, on patients.

- |   |  |
|---|--|
| <input type="checkbox"/> Leadership Position          | Board, officer, trustee, editor or other leadership position in commercial society or organization   |
| <input type="checkbox"/> Health Publishing            | Editorial boards and authors, including any publishing, royalty arrangements.  |
| <input type="checkbox"/> Consultant/Advisor           | Includes service on advisory boards.   |
| <input type="checkbox"/> Meeting Participant/Lecturer | Honoraria, reimbursements or in-kind payments received as faculty members, speakers' bureau, industry sponsored lectures, presenters, chairs, proctors or consultants. Any role which is beyond that of meeting attendee should be disclosed.  |
| <input type="checkbox"/> Scientific Study/Trial       | Includes research as a principle investigator as well as grant support for scientific studies or trials within a member's institution where a member has direct knowledge of these activities.   |
| <input type="checkbox"/> Investment Interest          | Personal or family stock ownership, dividends or revenue received from commercial interests providing healthcare or services. <b><i>Passive stock ownership such as mutual funds need not be disclosed.</i></b>                                |
| <input type="checkbox"/> Owner, Product Development   | Ownership in any commercial entity, including publishing, known outstanding patents, royalties, internet, e-commerce, ancillary services or other business enterprise that provides healthcare products or services related to AUA activities. |
| <input type="checkbox"/> Employee                     | Salaries from any commercial entity, including any publishing, internet, e-commerce or other business enterprise that provides healthcare products or services related to AUA activities.  |
| <input type="checkbox"/> Expert Witness               | Expert medical testimony for a trial, hearing, deposition, affidavit or any other type of legal proceeding   |
| <input type="checkbox"/> Other (please specify)       | <input style="width: 100%; height: 20px;" type="text"/>  |

5. General Memo Statement: Provide a brief description of the nature of the relationship being disclosed. (500 characters or less)

6. Indicate the length of time for the work itself, from initial conception and planning to the present. \_\_\_\_\_
7.  I have no direct or indirect commercial incentive associated with publishing the article.

**Signature** \_\_\_\_\_

**Ms. No.** \_\_\_\_\_

Please return signed form to: AUA, Publications Department, 1000 Corporate Blvd. Linthicum, MD 21090 (FAX: 410-689-3906)

### ***The Journal of Urology*® Author Submission Requirement Form**

**TITLE/Ms. No.:** \_\_\_\_\_

**Authors:** \_\_\_\_\_

Each author must read and electronically sign the statements below before manuscripts will be considered for publication in *The Journal of Urology*®. **Manuscripts submitted without all signatures on all statements or with illegible signatures will not be published.** This fillable form is available online at [www.editorialmanager.com/ju](http://www.editorialmanager.com/ju). One author should be designated as the correspondent, and the complete address, telephone number, facsimile number and e-mail address provided.

According to the International Committee of Medical Journal Editors (ICMJE) authorship is based on the following 4 criteria:

- Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors must meet ALL 4 criteria for authorship and must sign the Author Submission Requirement Form. Those who do meet ALL 4 criteria will be identified as authors and their names will be printed in the byline of the article.

**When a large, multicenter group or committee has conducted the work, the group should identify as authors only those individuals who fulfill ALL of the above requirements and accept direct responsibility for the manuscript. The corresponding author must clearly indicate the preferred citation and identify all individual authors as well as the group name.**

Contributors to the study who do not meet ALL 4 criteria of authorship will be acknowledged in an Appendix and identified as Collaborators so their names can be indexed in MEDLINE. Examples of contributions that do not justify authorship are acquisition of funding, general supervision of a research group, served as scientific advisors, critically reviewed the study proposal, collected data, provided and cared for study patients, and participated in writing or technical editing of the manuscript. Contributors do not have to sign the Author Submission Requirement Form.

#### I. Authorship Responsibility, Criteria and Contributions

A. By checking the appropriate boxes below, each author certifies that

- the manuscript represents valid and original work;
- the manuscript or portions thereof are not under consideration by another journal or electronic publication and have not been previously published except as an abstract;
- the manuscript or portions thereof have not been considered previously by *The Journal of Urology* and/or its supplements (including joint supplements);
- if requested I will provide raw data on which the manuscript is based for examination by the editors and reviewers;
- if I am the corresponding author I agree to be responsible for indicating the source of extra-institutional funding, in particular that provided by commercial sources, internal review board approval of study, accuracy of the references and all statements made in the work, including changes made by the copy editor, upon review of the proof; or if I am not the corresponding author I agree to assign the aforementioned responsibilities to the corresponding author;
- I have read and approve the final manuscript; and
- I have made a substantive contribution to the information or material submitted for publication to take public responsibility

B. To qualify for authorship each author must indicate his/her substantive contribution to the intellectual content of the manuscript by checking 1 box in Number 1, 1 box in Number 2 and 1 box in Number 3, and completing Number 4.

1.  Conception and design  
 Data acquisition  
 Data analysis and interpretation
2.  Drafting the manuscript  
 Critical revision of the manuscript for scientific and factual content
3.  Statistical analysis  
 Supervision  
 Other (specify) \_\_\_\_\_
4. Indicate the length of time for the work itself, from initial conception and planning to the present \_\_\_\_\_

II. Conflict of Interest/Disclosure Policy. Please check the appropriate box below

- I have no direct or indirect commercial financial incentive associated with publishing the article
- No funding agreement limits my ability to complete and publish this research/study
- I have full control of the primary data
- I have read and signed the AUA Disclosure Form.

III. Copyright Transfer. In consideration of the Editors of *The Journal of Urology*® taking action in reviewing and editing my submission, the author(s) undersigned hereby transfers, assigns or otherwise conveys all copyright ownership to the American Urological Association Education and Research, Inc., Copyright Owner of *The Journal of Urology*®, in the event that such work is published in The Journal. Authors employed by the U.S. Federal Government are exempt from Copyright Transfer. All authors have read and comply with the requirements set forth herein and in the Information for Authors.

\_\_\_\_\_  
Author Signature

\_\_\_\_\_  
Date Signed

The following 2 sections require only the Corresponding Author signature:

#### IV. Ethical approval of studies.

1. By checking the appropriate boxes the corresponding author certifies that a statement(s) has been included in the manuscript documenting

- Institutional review board, ethics committee or ethical review board study approval
- Institutional animal care and use committee approval
- In lieu of a formal ethics committee, the principles of the Helsinki Declaration were followed
- All human subjects provided written informed consent with guarantees of confidentiality

2. IRB approved protocol number is \_\_\_\_\_

3. **Clinical trial registration number is** \_\_\_\_\_

4. Animal approved project number is \_\_\_\_\_

V. Acknowledgment Statement. As corresponding author check the box below that applies:

- I certify that all individuals named in an Acknowledgment have given me permission to be named
- I certify that no other persons have made substantial contributions to this manuscript to warrant an Acknowledgement section.

\_\_\_\_\_  
Corresponding Author Signature

\_\_\_\_\_  
Date Signed